A.R.T. Advisors’s Paratek Pharmaceuticals, Inc. PRTK Stock Holding History

A.R.T. Advisors’s Portfolio PRTK Stock Details PRTK Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2019 Q3	–	Sell	-30,340	Closed	-$121K	–	1804
2019 Q2	$121K	Buy	+30,340	New	+$144K	0.01%	1167
2019 Q1	–	Sell	-67,918	Closed	-$348K	–	1700
2018 Q4	$348K	Buy	+67,918	New	+$516K	0.02%	870
2018 Q2	–	Sell	-73,137	Closed	-$950K	–	1842
2018 Q1	$950K	Buy	73,137 +56,600	+342%	+$843K	0.04%	687
2017 Q4	$296K	Buy	16,537 +2,000	+14%	+$41.7K	0.01%	1062
2017 Q3	$364K	Buy	+14,537	New	+$338K	0.02%	949
2015 Q3	–	Sell	-11,872	Closed	-$305K	–	1666
2015 Q2	$305K	Buy	+11,872	New	+$337K	0.01%	1179
2015 Q1	–	Sell	-5,191	Closed	-$200K	–	1759
2014 Q4	$200K	Buy	+5,191	New	+$124K	0.01%	1227

Other funds holding PRTK

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

OFM

Omega Fund Management Boston, Massachusetts $163M AUM 107.06% 1-Year Est. Return

Baupost Group Boston, Massachusetts $5.12B AUM 15.99% 1-Year Est. Return

Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

APCM

Arbiter Partners Capital Management New York $175M AUM 99.81% 1-Year Est. Return

Abingworth London, United Kingdom $307M AUM 93.47% 1-Year Est. Return

NAM

Nexpoint Asset Management Dallas, Texas $1.49B AUM 61.08% 1-Year Est. Return

RAM

Roumell Asset Management Chevy Chase, Maryland $53.3M AUM 8.91% 1-Year Est. Return

GAI

General American Investors New York $1.52B AUM 37.94% 1-Year Est. Return

A.R.T. Advisors's PRTK Position: Q3 2019 in Review

A.R.T. Advisors sold out of Paratek Pharmaceuticals, Inc. (PRTK) in Q3 2019, closing a stake of 30,340 shares — an estimated $121K sold.

A.R.T. Advisors first reported a position in PRTK in Q4 2014 and held it in 7 quarters. The position peaked at $950K in Q1 2018. 91 funds tracked by Wall St. Rank hold PRTK as of Q3 2019.

A.R.T. Advisors reported no remaining Paratek Pharmaceuticals, Inc. position as of Q3 2019 after selling out during the quarter.
A.R.T. Advisors sold 30,340 Paratek Pharmaceuticals, Inc. shares in Q3 2019, an estimated $121K.
A.R.T. Advisors first reported a position in Paratek Pharmaceuticals, Inc. in Q4 2014 and held it in 7 quarters.
A.R.T. Advisors's Paratek Pharmaceuticals, Inc. position peaked at $950K in Q1 2018.
91 funds tracked by Wall St. Rank held Paratek Pharmaceuticals, Inc. as of Q3 2019.

Based on A.R.T. Advisors's 13F filing for Q3 2019, filed 14 Nov 2019.